Reimbursement agencies are increasingly likely to require some economic data to back the claims on the superior value of biotech drugs compared to traditional ones.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Author notes
Additional reporting by Alla Katsnelson, New York.
- Alla Katsnelson
Related links
Related links
Related links in Nature Research
Therapeutic area influences drug development costs
EU to review rare disease drugs market exclusivity
New rules for US drug reimbursement
Related external links
Rights and permissions
About this article
Cite this article
Sheridan, C., Katsnelson, A. Cost-effectiveness data on biologics needed. Nat Biotechnol 23, 272–273 (2005). https://doi.org/10.1038/nbt0305-272
Issue Date:
DOI: https://doi.org/10.1038/nbt0305-272
This article is cited by
-
Socio-economic aspects of neuroimmunological diseases
Journal of Neurology (2006)
